Teva may buy more Mylan stock despite antitrust allegations

Harry Phillips

03 June 2015

Mylan's lucrative EpiPen is one reason Teva is pushing its $42 billion merger offer. (Credit: Roel Smart)

Subscribe to Global Competition Review

Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.

Subscribe now

View full biography

Author

[email protected]

A Powers trip: The Tipline for 28 September 2022
Who could forget when Uncle Ben warned Peter Parker about the dangers of collusion? “With great Powers comes great responsibility,” Spiderman’s uncle said, in a clear reference to the potential for criminal liability should he consider violating Section 1 of the Sherman Act during the tenure of deputy assistant attorney general Richard Powers. The Department of Justice’s top antitrust prosecutor has now departed for private practice, perhaps freeing up an opportunity for Spiderman to …
The Fall Classic: The Tipline for 27 September 2022
The partiality of Judge Khan: The Tipline for 26 September 2022